HOME >> MEDICINE >> NEWS
Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

line therapy. They may not be effective, however, in patients who have previously had treatment with this class of drugs. Patients who are responding to HAART may be doing well enough that they don't need prophylaxis, she said.

"The risks versus benefits must be carefully evaluated. We want to protect patients from MAC, but we also want to prevent them from developing resistance to antibiotics," said Aberg, who is a UCSF assistant professor of medicine and also treats patients at San Francisco General.

In the pre-HAART era, macrolides were standard treatment as prevention therapy against MAC infection in AIDS patients whose CD4+ counts were below 75, according to Aberg. Now with HAART, many patients may have CD4+ counts that are higher.

The main conclusion from study findings, she said, is that careful consideration should be given to continuing use of macrolides for MAC prophylaxis when CD4+ counts have increased and to using macrolides for infection treatment if a patient has been on a macrolide previously.

Both research studies were supported by grants from the NIH UCSF Center for AIDS Research and the UC Universitywide AIDS Research Program,

In addition, the CMV retinitis study received a grant from Research to Prevent Blindness, Inc., and the macrolide bacterial resistance study received support from Abbott Laboratories.


'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
27-Sep-1999


Page: 1 2 3

Related medicine news :

1. Most episodes of HIV blips not clinically significant in patients receiving HAART
2. Multiple characteristics of HAART affect adherence
3. Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment
4. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
5. Old Drugs, New Tricks
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Study finds that coordinating care of chronically ill patients does not increase liability
8. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
9. Optical technique identifies vulnerable plaques in cardiac patients
10. NHS target driven culture is failing patients
11. Cardiac deaths peak in sleep hours for patients with sleep apnea

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
Cached News: